Nick Paul Taylor

Almost two-thirds of Americans who have asked artificial intelligence tools for medical advice acted on the guidance without consulting a doctor, an eHealth survey of more than 1,000 peop

The company plans to eliminate 119 positions by mid-December as part of a phased transfer of some production from the manufacturing site.

Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, furthering the drugmaker’s efforts to improve on-screen representations of peop

Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.

Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival (PFS), adding to evidence that the off-the-shelf treatment can match the eff

Madrigal Pharmaceuticals has installed a 20-foot-tall, 41-foot-wide inflatable liver in a Philadelphia park to mark Global Fatty Liver Awareness Day.

CEO Rainer Blair said Danaher has the money and “leadership bandwidth” to strike further deals across any of its three business areas.

Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.

Officials sanctioned Dabur India months after FDA inspectors found bird droppings and data integrity deficiencies during an inspection of the plant.

The correction is the latest recall that J&J’s Abiomed has issued in recent years for Impella devices and controllers.